-

Mitsubishi Electric, Okayama University, and Osaka University Develop Magnetic Particle Imaging Device Capable of Producing Images of Human Brain

The world's first high-sensitivity imaging device capable of operating at low frequencies with compact power supply, will facilitate diagnosis of pre-Alzheimer's

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503), Okayama University and Osaka University’s Graduate School of Engineering announced today that they have developed a magnetic particle imaging device capable of sensitive imaging of magnetic particles in an area equivalent in size to that of the human brain, in a project supported by the Japan Agency for Medical Research and Development (AMED). The device operates at low frequencies of 1 kHz or less, a world-first, allowing the use of a significantly smaller power supply unit. The utilization of this device to image magnetic particles that bind to amyloid-β, the causative agent of Alzheimer's, will allow the accumulation and distribution of amyloid-β to be quantified. The aim is to allow imaging-based assessments of the likelihood of Alzheimer's developing prior to the onset of the disease.

The number of dementia patients aged 65 and older in Japan is expected to reach 7 million in 2025. Significant statistical findings indicate that Alzheimer's accounts for 67.6% of these dementia cases. In June of this year, Japan enacted the Dementia Basic Law, aimed at advancing dementia prevention efforts. In August, a panel of experts from Japan's Ministry of Health, Labour and Welfare gave a green light for the manufacture and sale of a drug that targets the accumulation of amyloid-β in the brain, a potential factor in the development of Alzheimer’s, thereby inhibiting the progression of the disease. Initiating medication early during a phase of low amyloid-β accumulation in the brain has been shown to help suppress the onset of the disease. This underscores the necessity for technology capable of measuring both the accumulation and distribution of amyloid-β.

For the full text, please visit: www.MitsubishiElectric.com/news/

Contacts

Media Inquiries
Takeyoshi Komatsu
Public Relations Division
Mitsubishi Electric Corporation
Tel: +81-3-3218-2346
prd.gnews@nk.MitsubishiElectric.co.jp
www.MitsubishiElectric.com/news/

Mitsubishi Electric Corporation

TOKYO:6503

Release Versions

Contacts

Media Inquiries
Takeyoshi Komatsu
Public Relations Division
Mitsubishi Electric Corporation
Tel: +81-3-3218-2346
prd.gnews@nk.MitsubishiElectric.co.jp
www.MitsubishiElectric.com/news/

More News From Mitsubishi Electric Corporation

Mitsubishi Electric to Ship Samples of XB Series HVIGBT Module

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it will begin shipping samples of its new XB Series high-voltage insulated-gate bipolar transistor (HVIGBT) module, a 3.3k-volt, 1500A high-capacity power semiconductor for large industrial equipment such as railway vehicles, on May 1. By adopting proprietary diode and insulated gate bipolar transistor (IGBT) elements, as well as a unique chip termination structure, the module’s improved moisture resistan...

Mitsubishi Electric to Support Earthquake Relief in Myanmar

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it will donate a total of 10 million yen to aid victims and support recovery efforts following the earthquake that struck Myanmar on March 28. The donation will be made through the Japanese Red Cross Society to support rescue and relief efforts as well as disaster prevention and mitigation activities in Myanmar and Thailand, which will be conducted by the International Red Cross and Red Crescent, the Inte...

Mitsubishi Electric Announces Director Candidates

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that the candidates for Directors, who will be proposed for election at the Ordinary General Meeting of Shareholders scheduled in June 2025, were elected at the company’s Nomination Committee meeting held earlier today. 1. Director Candidates (current positions) Tatsuro Kosaka (Director (Senior Advisor, CHUGAI PHARMACEUTICAL CO., LTD.)) Hiroyuki Yanagi (Director (Adviser, Yamaha Motor Co., Ltd.)) Masako Egawa...
Back to Newsroom